A Phase 3 interventional study of ABC/DTG/3TC FDC and Ongoing cART regimen in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 103 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-04.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a 48-week, Phase IIIb, randomly assigned, open-label, active-controlled, multicenter, parallel group, non-inferiority study. This study is designed to demonstrate the non-inferior antiviral activity of switching to the Abacavir (ABC) 600 milligrams (mg)/Dolutegravir(DTG) 50 mg/Lamivudine (3TC) 300 mg fixed-dose combination (FDC) compared with continuing the subject's current suppressive regimen through 24 weeks. The study will be conducted in approximately 538 Human Immunodeficiency Virus -1 (HIV-1) infected individuals who are on stable suppressive combination antiretroviral therapy (cART) with 2 Nucleoside reverse transcriptase inhibitors (NRTIs) plus either a protease inhibitor (PI), an non-nucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor (INI). Eligible subjects will be randomly assigned 1:1 to continue their current regimen (approximately 269 subjects) or be switched to ABC/DTG/3TC FDC (approximately 269 subjects) once daily for 24 weeks. At Week 24, individuals originally randomly assigned to continue their current regimen will switch to ABC/DTG/3TC FDC and be followed for an additional 24 weeks. Individuals initially randomly assigned to ABC/DTG/3TC FDC will continue on that treatment arm for an additional 24 weeks. A pharmacokinetic (PK) substudy will be conducted at a small number of sites (approximately 10) to evaluate predose DTG concentrations as well as residual drug concentrations of efavirenz (EFV), nevaripine (NVP), amprenavir (APV) and tipranavir (TPV) in a subgroup of subjects who switch from EFV, NVP, fosamprenavir/ritonavir (FPV/r) or tipranavir/ritonavir (TPV/r).
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 555 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Exclusion Criteria:
Exclusionary Medical Conditions
Exclusionary Treatments Prior to Screening or Day 1
Exclusionary Laboratory Values or Clinical Assessments at Screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will take ABC 600 mg/DTG 50 mg/3TC 300 mg FDC once daily in the morning or the evening, at approximately the same time each day for 24 weeks. After Week 24, subjects will continue on this treatment arm for an additional 24 weeks.
Drug: ABC/DTG/3TC FDC
Subjects will continue on their current Combination antiretroviral therapy (cART) regimen for 24 weeks. At Week 24, subjects will switch to ABC/DTG/3TC FDC for an additional 24 weeks.
Drug: Ongoing cART regimen
Drug pages: Dolutegravir · Lamivudine
Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 24 Using the Snapshot Algorithm
The Food and Drug Administration (FDA) snapshot (Missing, Switch or Discontinuation = Failure) algorithm is intended to be primarily a virologic assessment of the endpoint, and as such follows a "virology first" hierarchy. Virologic Success (e.g., \<50 c/mL) or virologic failure within an analysis window is typically determined by the last available HIV-1 RNA measurement in that window and in the treatment phase of interest (e.g., Week 24 snapshot outcomes of the early switch phase will not use HIV-1 RNA data from the late switch phase, even if such data is within the Week 24 analysis window). A virologic failure occurs when a participant changes to their ART regimen (e.g., addition of other ARTs to the study-specified regimens, or switches in components of the current ART regimen).
Time frame: Week 24
Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 24
Change from Baseline in CD4+ cell counts were assessed at Baseline, Weeks 4, 8, 16 and 24. No imputation for missing data or premature discontinuation was performed and the observed values were used. Baseline value is defined as the last pre-treatment value observed. Change from Baseline was calculated as the observed value minus the Baseline value. The Week 24 data were summarized.
Time frame: Baseline and Week 24
Number of Participants in the Virologic Non-response Category From the Snapshot Analysis at Week 24
Virologic non-responders were defined as the participants with a viral load \>=50 c/mL in the Week 24 analysis window. Virologic non-response includes participants who had HIV-1 RNA \>=50 c/mL, who discontinued for lack of efficacy, who discontinued for other reasons while not suppressed, data in window but not \<50 c/mL, and who changed ART regimen at Week 24. Difference is calculated as the proportion on ABC/DTG/3TC - proportion on current ART regimen.
Time frame: Week 24
Number of Participants With Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 24 Weeks
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgment and all events of possible drug-induced liver injury with hyperbilirubinemia. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS estimates the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.
Time frame: Baseline and up to 24 weeks
Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to 24 Weeks
The number of participants with maximum post-Baseline emergent chemistry toxicities for each grade were summarized by parameter. A toxicity is considered emergent if it develops or increases in intensity from Baseline. For participants who were originally randomized to current ART regimen on Day 1 and then switched to ABC/DTG/3TC on Week 24, Baseline is defined as the last non-missing value from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.
Time frame: Baseline and up to 24 weeks
Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to 24 Weeks
The number of participants with maximum post-Baseline emergent hematology toxicities for each grade were summarized by parameter. A toxicity is considered emergent if it develops or increases in intensity from Baseline. For participants who were originally randomized to current ART regimen on Day 1 and then switched to ABC/DTG/3TC on Week 24, Baseline is defined as the last non-missing value from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.
Time frame: Baseline and up to 24 weeks
Number of Participants With AEs Leading to Withdrawal Over 24 Weeks
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgment and all events of possible drug-induced liver injury with hyperbilirubinemia.
Time frame: Baseline and up to 24 weeks
Change From Baseline in Fasting Lipids (Cholesterol, LDL Cholesterol, HDL Cholesterol, and Triglycerides) at Week 24
Change from Baseline for each fasting lipid parameters included cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Adjusted mean is the estimated mean change from Baseline in each parameter at Week 24 in each arm calculated from an analysis of covariance (ANCOVA) model which includes the following covariates: treatment, original ART third agent class, interaction of treatment and original ART 3rd agent, use of lipid modifying agent and Baseline lipid level. Difference is calculated as ABC/DTG/3TC - Current ART regimen. For fasting lipid assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast was acceptable for participants with afternoon appointments.
Time frame: Baseline and Week 24
Change From Baseline in Fasting Lipids (Total Cholesterol/HDL Cholesterol Ratio) at Week 24
Change from Baseline for fasting lipid parameter total cholesterol/HDL cholesterol ratio. Adjusted mean is the estimated mean change from Baseline at Week 24 in each arm calculated from an analysis of covariance (ANCOVA) model which includes the following covariates: treatment, original ART third agent class, interaction of treatment and original ART 3rd agent, use of lipid modifying agent and Baseline lipid level. Difference is calculated as ABC/DTG/3TC - Current ART regimen. For fasting lipid assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast was acceptable for participants with afternoon appointments.
Time frame: Baseline and Week 24
Change From Baseline in Treatment Satisfaction at Week 4 and Week 24
The HIV treatment satisfaction questionnaire (TSQ) is a 10 item self-reported scale. Individual item scores range from 6 (very satisfied) to 0 (very dissatisfied). The treatment satisfaction total score (range 0-60) is the sum of all the 10 individual items. The general satisfaction/Clinical subscale (range 0-30) is the sum of the 5 clinical items and the lifestyle/ease subscale (range 0-30) is the sum of the remaining 5 lifestyle items. Last observation carried forward (LOCF) were used for the analysis. If a participant had a missing value at Week 24, his previous non-missing available value while on the same treatment was carried forward (ie the Week 4 or withdrawal value is used in the Week 24 summary for participants in the ABC/DTG3TC with missing Week 24 value). Data were analyzed using an ANCOVA model with factors including treatment, Baseline score and stratification factor. Treatment group difference (ABC/DTG/3TC-cART) estimate and 95% CI were presented.
Time frame: Baseline, Week 4 and Week 24
Change From Baseline in Creatinine at Week 24
Renal markers included creatinine and summarized based on an observed case (OC) data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
Time frame: Baseline and Week 24
Change From Baseline in Glomerular Filtration Rate (GFR) From Creatinine Adjusted Using CKD-EPI Equation at Week 24
Renal markers included GFR from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI) equation and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
Time frame: Baseline and Week 24
Change From Baseline in GFR From Creatinine Adjusted Using MDRD Enzymatic Equation at Week 24
Renal markers included GFR from creatinine adjusted using modification of diet in renal disease (MDRD) enzymatic equation and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
Time frame: Baseline and Week 24
Change From Baseline in Urea at Week 24
Renal markers included urea and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
Time frame: Baseline and Week 24
Change From Baseline in Urine Albumin/Creatinine Ratio at Week 24
Renal markers included urine albumin/creatinine ratioand summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
Time frame: Baseline and Week 24
Percent Change From Baseline in Bone Marker Analytes at Week 24
Outcome Measure Description: Bone biomarkers analytes include bone specific alkaline phosphatase, osteocalcin, procollagen 1 n-terminal propeptide, type I collagen c-telopeptides and were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, age, sex (male or female), body mass index (BMI) (\<25 kilogram per meter \[kg/m\] or \>=25 kg/m), smoking status (never smoked or former smoker or current smoker), Baseline vitamin D (no vitamin D use at Baseline or vitamin D use at Baseline), and Baseline biomarker level.
Time frame: Baseline and Week 24
Percent Change From Baseline in Cardiovascular Marker Analytes at Week 24
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.
Time frame: Baseline and Week 24
Percent Change From Baseline in Cardiovascular Marker Analyte, C-reactive Protein at Week 24
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.
Time frame: Baseline and Week 24
Percent Change From Baseline in Cardiovascular Marker Analyte, D-Dimer at Week 24
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.
Time frame: Baseline and Week 24
Percent Change From Baseline in Cardiovascular Marker Analyte, Homostat Model Assess of Insulin Resistance at Week 24
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.
Time frame: Baseline and Week 24
Percent Change From Baseline in Cardiovascular Marker Analyte, Insulin at Week 24
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.
Time frame: Baseline and Week 24
Percent Change From Baseline in Cardiovascular Marker Analyte, Soluble CD163 at Week 24
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.
Time frame: Baseline and Week 24
Percent Change From Baseline in Cardiovascular Marker Analyte, Glucose at Week 24
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.
Time frame: Baseline and Week 24
Number of Participants With Incidence of Genotypic and Phenotypic Resistance Meeting Confirmed Virologic Withdrawal Criteria Over 24 Weeks
Genotypic and phenotypic testing was conducted for participants who met the confirmed virologic withdrawal criteria, i.e., confirmed HIV-1 RNA \>=400 c/mL any time after Day 1. The sample from the "suspected virologic withdrawal criterion" visit was tested for HIV-1 PRO and RT genotype and phenotype and HIV-1 integrase genotype and phenotype (i.e., the first of the two consecutive results \>=400 c/mL). At the time of the data cut-off for this Week 24 analysis, no participants met the confirmed virologic withdrawal criteria over 24 weeks; therefore, the virologic analyses were not assessed.
Time frame: Baseline and up to 24 weeks
| Milestone | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch:Cont Phase | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch:Cont Phase |
|---|---|---|---|---|---|---|
| Started | 275 | 278 | 0 | 0 | 0 | 0 |
| Completed | 239 | 244 | 0 | 0 | 0 | 0 |
| Not completed | 36 | 34 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 10 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 15 | 17 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 10 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 4 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Missing disposition data | 0 | 1 | 0 | 0 | 0 | 0 |
| Milestone | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch:Cont Phase | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch:Cont Phase |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 275 | 244 | 0 | 0 |
| Completed | 0 | 0 | 230 | 230 | 0 | 0 |
| Not completed | 0 | 0 | 45 | 14 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 10 | 4 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 15 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 8 | 3 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Met protocol defined stopping criteria | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Per sponsor request | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Early Switch:Cont Phase | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC Late Switch:Cont Phase |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 14 | 23 |
| Completed | 0 | 0 | 0 | 0 | 13 | 23 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 |
The Food and Drug Administration (FDA) snapshot (Missing, Switch or Discontinuation = Failure) algorithm is intended to be primarily a virologic assessment of the endpoint, and as such follows a "virology first" hierarchy. Virologic Success (e.g., \<50 c/mL) or virologic failure within an analysis window is typically determined by the last available HIV-1 RNA measurement in that window and in the treatment phase of interest (e.g., Week 24 snapshot outcomes of the early switch phase will not use HIV-1 RNA data from the late switch phase, even if such data is within the Week 24 analysis window). A virologic failure occurs when a participant changes to their ART regimen (e.g., addition of other ARTs to the study-specified regimens, or switches in components of the current ART regimen).
| Participants | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies Per Milliliter (c/mL) at Week 24 Using the Snapshot Algorithm | 233 | 245 |
Change from Baseline in CD4+ cell counts were assessed at Baseline, Weeks 4, 8, 16 and 24. No imputation for missing data or premature discontinuation was performed and the observed values were used. Baseline value is defined as the last pre-treatment value observed. Change from Baseline was calculated as the observed value minus the Baseline value. The Week 24 data were summarized.
| Cells per cubic millimeter (cells/mm^3) | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Week 24 | 50.0 (-48.0 to 130.0) | 11.0 (-60.0 to 103.5) |
Virologic non-responders were defined as the participants with a viral load \>=50 c/mL in the Week 24 analysis window. Virologic non-response includes participants who had HIV-1 RNA \>=50 c/mL, who discontinued for lack of efficacy, who discontinued for other reasons while not suppressed, data in window but not \<50 c/mL, and who changed ART regimen at Week 24. Difference is calculated as the proportion on ABC/DTG/3TC - proportion on current ART regimen.
| Participants | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Number of Participants in the Virologic Non-response Category From the Snapshot Analysis at Week 24 | 3 | 4 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgment and all events of possible drug-induced liver injury with hyperbilirubinemia. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS estimates the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.
| Participants | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Any AEs | 183 | 129 |
| Any SAEs | 6 | 5 |
The number of participants with maximum post-Baseline emergent chemistry toxicities for each grade were summarized by parameter. A toxicity is considered emergent if it develops or increases in intensity from Baseline. For participants who were originally randomized to current ART regimen on Day 1 and then switched to ABC/DTG/3TC on Week 24, Baseline is defined as the last non-missing value from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.
| Participants | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Grade 1 | 98 | 108 |
| Grade 2 | 73 | 71 |
| Grade 3 | 21 | 25 |
| Grade 4 | 10 | 10 |
The number of participants with maximum post-Baseline emergent hematology toxicities for each grade were summarized by parameter. A toxicity is considered emergent if it develops or increases in intensity from Baseline. For participants who were originally randomized to current ART regimen on Day 1 and then switched to ABC/DTG/3TC on Week 24, Baseline is defined as the last non-missing value from the early switch phase and maximum post-Baseline emergent during the late switch phase was determined relative to this Baseline. The DAIDS table for grading the severity of adult and pediatric AEs was utilized for AE reporting. The DAIDS defined the severity grade as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life threatening) for each parameter.
| Participants | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Grade 1 | 19 | 15 |
| Grade 2 | 3 | 6 |
| Grade 3 | 0 | 2 |
| Grade 4 | 1 | 0 |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, based on medical or scientific judgment and all events of possible drug-induced liver injury with hyperbilirubinemia.
| Participants | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Number of Participants With AEs Leading to Withdrawal Over 24 Weeks | 11 | 0 |
Change from Baseline for each fasting lipid parameters included cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. Adjusted mean is the estimated mean change from Baseline in each parameter at Week 24 in each arm calculated from an analysis of covariance (ANCOVA) model which includes the following covariates: treatment, original ART third agent class, interaction of treatment and original ART 3rd agent, use of lipid modifying agent and Baseline lipid level. Difference is calculated as ABC/DTG/3TC - Current ART regimen. For fasting lipid assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast was acceptable for participants with afternoon appointments.
| Millimoles per liter (mmol/L) | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Cholesterol,n=226, 231 | 0.10 (0.00 to 0.21) | -0.01 (-0.11 to 0.10) |
| LDL Cholesterol, n=221, 226 | 0.10 (0.01 to 0.18) | 0.02 (-0.06 to 0.11) |
| HDL Cholesterol, n=226, 231 | 0.00 (-0.04 to 0.03) | -0.03 (-0.06 to 0.01) |
| Triglycerides, n=226, 231 | 0.07 (-0.07 to 0.21) | -0.04 (-0.17 to 0.10) |
Change from Baseline for fasting lipid parameter total cholesterol/HDL cholesterol ratio. Adjusted mean is the estimated mean change from Baseline at Week 24 in each arm calculated from an analysis of covariance (ANCOVA) model which includes the following covariates: treatment, original ART third agent class, interaction of treatment and original ART 3rd agent, use of lipid modifying agent and Baseline lipid level. Difference is calculated as ABC/DTG/3TC - Current ART regimen. For fasting lipid assessments, an overnight fast is preferred; however, a minimum of a 6-hour fast was acceptable for participants with afternoon appointments.
| Ratio | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Change From Baseline in Fasting Lipids (Total Cholesterol/HDL Cholesterol Ratio) at Week 24 | 0.10 (-0.02 to 0.22) | 0.00 (-0.12 to 0.12) |
The HIV treatment satisfaction questionnaire (TSQ) is a 10 item self-reported scale. Individual item scores range from 6 (very satisfied) to 0 (very dissatisfied). The treatment satisfaction total score (range 0-60) is the sum of all the 10 individual items. The general satisfaction/Clinical subscale (range 0-30) is the sum of the 5 clinical items and the lifestyle/ease subscale (range 0-30) is the sum of the remaining 5 lifestyle items. Last observation carried forward (LOCF) were used for the analysis. If a participant had a missing value at Week 24, his previous non-missing available value while on the same treatment was carried forward (ie the Week 4 or withdrawal value is used in the Week 24 summary for participants in the ABC/DTG3TC with missing Week 24 value). Data were analyzed using an ANCOVA model with factors including treatment, Baseline score and stratification factor. Treatment group difference (ABC/DTG/3TC-cART) estimate and 95% CI were presented.
| Units on a scale | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Total score, n=270,276 | 3.2 ± 0.40 | 0.8 ± 0.39 |
| General Satisfaction/Clinical Subscale, n=269, 276 | 1.3 ± 0.24 | 0.2 ± 0.23 |
| Lifestyle/Ease Subscale Score, n=269, 276 | 1.8 ± 0.19 | 0.6 ± 0.19 |
Renal markers included creatinine and summarized based on an observed case (OC) data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
| Micromoles per liter (umol/L) | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Change From Baseline in Creatinine at Week 24 | 7.63 (6.46 to 8.80) | 1.12 (-0.03 to 2.27) |
Renal markers included GFR from creatinine adjusted using chronic kidney disease epidemiology collaboration (CKD-EPI) equation and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
| mL/second | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Change From Baseline in Glomerular Filtration Rate (GFR) From Creatinine Adjusted Using CKD-EPI Equation at Week 24 | -8.05 (-9.30 to -6.80) | -1.18 (-2.41 to 0.06) |
Renal markers included GFR from creatinine adjusted using modification of diet in renal disease (MDRD) enzymatic equation and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
| mL/second/1.73 meter square | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Change From Baseline in GFR From Creatinine Adjusted Using MDRD Enzymatic Equation at Week 24 | -0.16 (-0.18 to -0.13) | -0.02 (-0.04 to 0.00) |
Renal markers included urea and summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
| Millimoles per liter (mmol/L) | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Change From Baseline in Urea at Week 24 | -0.03 (-0.18 to 0.12) | 0.07 (-0.08 to 0.22) |
Renal markers included urine albumin/creatinine ratioand summarized based on an OC data set at Week 24. Adjusted mean is the estimated mean change from Baseline in each biomarker at Week 24 in each arm calculated from an ANCOVA analysis of covariance model including the following covariates: treatment, original ART third agent class, interaction of treatment and original ART third agent class, and Baseline biomarker level. Differences are calculated as ABC/DTG/3TC - Current ART regimen.
| Gram per mole (G/mol) creatinine | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Change From Baseline in Urine Albumin/Creatinine Ratio at Week 24 | 0.11 (-0.70 to 0.92) | -0.07 (-0.84 to 0.69) |
Outcome Measure Description: Bone biomarkers analytes include bone specific alkaline phosphatase, osteocalcin, procollagen 1 n-terminal propeptide, type I collagen c-telopeptides and were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, age, sex (male or female), body mass index (BMI) (\<25 kilogram per meter \[kg/m\] or \>=25 kg/m), smoking status (never smoked or former smoker or current smoker), Baseline vitamin D (no vitamin D use at Baseline or vitamin D use at Baseline), and Baseline biomarker level.
| Percent | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Bone specific alkaline phosphatase, n= 214, 224 | 0.84 (0.79 to 0.88) | 0.98 (0.93 to 1.03) |
| Osteocalcin, n=211, 221 | 0.87 (0.82 to 0.93) | 0.96 (0.90 to 1.03) |
| Procollagen 1 n-terminal propeptide, n=212, 222 | 0.88 (0.83 to 0.94) | 0.96 (0.91 to 1.03) |
| Type I collagen c-telopeptides, n=212, 223 | 0.87 (0.79 to 0.95) | 1.03 (0.94 to 1.14) |
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.
| Percent | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Fatty acid binding protein 2 [ng/L], n=212,222 | 0.67 (0.59 to 0.75) | 1.04 (0.92 to 1.17) |
| Interleukin 6 [ng/L], n=213,222 | 0.86 (0.74 to 0.99) | 0.80 (0.69 to 0.92) |
| Soluble cd14 [ng/L], n=214,223 | 0.76 (0.73 to 0.79) | 0.82 (0.79 to 0.85) |
| Soluble vasc cell adhesion mol 1[ng/L], n=213,222 | 0.86 (0.80 to 0.92) | 0.85 (0.80 to 0.91) |
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.
| Percent | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Percent Change From Baseline in Cardiovascular Marker Analyte, C-reactive Protein at Week 24 | 1.25 (1.04 to 1.50) | 1.25 (1.04 to 1.49) |
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or African American, Other), and Baseline biomarker level.
| Percent | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Percent Change From Baseline in Cardiovascular Marker Analyte, D-Dimer at Week 24 | 1.00 (0.91 to 1.10) | 1.00 (0.91 to 1.10) |
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.
| Percent | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Percent Change From Baseline in Cardiovascular Marker Analyte, Homostat Model Assess of Insulin Resistance at Week 24 | 0.97 (0.84 to 1.11) | 1.00 (0.87 to 1.14) |
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.
| Percent | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Percent Change From Baseline in Cardiovascular Marker Analyte, Insulin at Week 24 | 0.97 (0.86 to 1.09) | 0.99 (0.88 to 1.12) |
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.
| Percent | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Percent Change From Baseline in Cardiovascular Marker Analyte, Soluble CD163 at Week 24 | 1.09 (1.04 to 1.15) | 1.08 (1.02 to 1.13) |
Cardiovascular biomarkers were analyzed based on log transformed data. Estimates were from an ANCOVA model adjusting for ART third agent class, interaction of treatment and original ART third agent class, sex, race (white, black or african american, other), and Baseline biomarker level.
| Percent | ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Current ART |
|---|---|---|
| Percent Change From Baseline in Cardiovascular Marker Analyte, Glucose at Week 24 | 1.02 (0.99 to 1.05) | 1.01 (0.99 to 1.04) |
Genotypic and phenotypic testing was conducted for participants who met the confirmed virologic withdrawal criteria, i.e., confirmed HIV-1 RNA \>=400 c/mL any time after Day 1. The sample from the "suspected virologic withdrawal criterion" visit was tested for HIV-1 PRO and RT genotype and phenotype and HIV-1 integrase genotype and phenotype (i.e., the first of the two consecutive results \>=400 c/mL). At the time of the data cut-off for this Week 24 analysis, no participants met the confirmed virologic withdrawal criteria over 24 weeks; therefore, the virologic analyses were not assessed.
No measurements were reported for this outcome.
Collected over Early Switch group AEs/SAEs are included from time of switch to ABC 600mg/DTG 50mg/3TC 300mg at baseline up to Week 48. Late Switch group AEs/SAEs are included from the time of switch to ABC 600mg/DTG 50mg/3TC 300mg at week 24 up to Week 48.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | — | 9/275 (3.3%) | 101/275 (36.7%) |
| Late Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | — | 6/244 (2.5%) | 61/244 (25%) |
| Event | Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Late Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC |
|---|---|---|
| Myocardial infarctionCardiac disorders | 0/275 | 1/244 |
| DiverticulitisInfections and infestations | 0/275 | 1/244 |
| Subcutaneous abscessInfections and infestations | 0/275 | 1/244 |
| Femur fractureInjury, poisoning and procedural complications | 0/275 | 1/244 |
| Alanine aminotransferase increasedInvestigations | 0/275 | 1/244 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/275 | 1/244 |
| Cardiac failure congestiveCardiac disorders | 1/275 | 0/244 |
| CellulitisInfections and infestations | 1/275 | 0/244 |
| GastroenteritisInfections and infestations | 1/275 | 0/244 |
| Pneumonia bacterialInfections and infestations | 1/275 | 0/244 |
| Event | Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Late Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 35/275 | 22/244 |
| NauseaGastrointestinal disorders | 28/275 | 15/244 |
| FatigueGeneral disorders | 22/275 | 6/244 |
| DiarrhoeaGastrointestinal disorders | 20/275 | 9/244 |
| HeadacheNervous system disorders | 17/275 | 10/244 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/275 | 6/244 |
| InsomniaPsychiatric disorders | 14/275 | 9/244 |
| Age, Continuous(Years) | Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Late Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Total |
|---|---|---|---|
| Mean | 44.1 ± 10.61 | 45.5 ± 11.25 | 44.8 ± 10.93 |
| Gender(Participants) | Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Late Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Total |
|---|---|---|---|
| Female | 38 | 32 | 70 |
| Male | 237 | 212 | 449 |
| Race/Ethnicity, Customized(Participants) | Early Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Late Switch ABC 600 mg / DTG 50 mg /3TC 300 mg FDC | Total |
|---|---|---|---|
| African American/African Heritage | 81 | 63 | 144 |
| American Indian or Alaska Native | 3 | 2 | 5 |
| Asian - Central/South Asian Heritage | 1 | 2 | 3 |
| Asian - East Asian Heritage | 1 | 3 | 4 |
| Asian - Japanese Heritage | 1 | 1 | 2 |
| Asian - South East Asian Heritage | 1 | 2 | 3 |
| Asian - Mixed Race | 1 | 0 | 1 |
| Native Hawaiian or other Pacific Islander | 1 | 1 | 2 |
| White - Arabic/North African Heritage | 2 | 0 | 2 |
| White - White/Caucasian/European Heritage | 176 | 165 | 341 |
| White - Mixed Race | 3 | 3 | 6 |
| White - Asian | 1 | 1 | 2 |
| Mixed Race | 1 | 1 | 2 |
| Missing | 2 | 0 | 2 |
Showing the first 100 of 103 sites across 3 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2014, a primary completion of Apr 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dolutegravir · Lamivudine